drugset / Trial / NCT04205838
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
NaSingle-groupOpen-labelPrevention
Summary
This phase II trial studies how well anakinra works in preventing severe chimeric antigen receptor T-cell-related encephalopathy syndrome after chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma that has come back or has not responded to treatment. Immunosuppressive therapy, such as anakinra, is used to decrease the body?s immune response, which may prevent severe chimeric antigen receptor T-cell-related encephalopathy syndrome.
Timeline
- Start
- 2020-03-04
- Primary completion
- 2026-02-19
- Completion
- 2026-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | — | Subcutaneous |
| Background | Axicabtagene Ciloleucel | Cell therapy | — | Other |
| Background | Cyclophosphamide | Other / unclassified | — | Other |
| Background | Fludarabine | Small molecule | — | Other |